Black Diamond Therapeutics (BDTX) Prepaid Assets (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Prepaid Assets came in at $4.7 million in Q1 2026, up 43.61% YoY from $3.3 million in Q1 2025, and up 24.31% on a QoQ basis from $3.8 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Prepaid Assets (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Prepaid Assets data on file, last reported at $4.7 million in Q1 2026.
- Quarterly Prepaid Assets rose 43.61% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 43.61% YoY) and the FY2025 annual result came in at $3.8 million, up 45.64% from the prior year.
- Prepaid Assets climbed to $4.7 million in Q1 2026, from $3.8 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $8.6 million in Q1 2022 to a low of $2.6 million in Q4 2024.
- A 5-year average of $4.3 million and a median of $3.8 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2023 — Prepaid Assets slumped 58.91% — and 2025, when it surged 45.64%.
- Tracing BDTX's Prepaid Assets over 5 years: stood at $4.9 million in 2022, then tumbled by 46.23% to $2.6 million in 2023, then retreated by 1.25% to $2.6 million in 2024, then surged by 45.64% to $3.8 million in 2025, then climbed by 24.31% to $4.7 million in 2026.
- The last three Prepaid Assets figures came in at $4.7 million (Q1 2026), $3.8 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.89 Mn |
| Mar 31, 2026 | 4.71 Mn |
| Dec 31, 2025 | 3.79 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Mar 31, 2025 | 3.28 Mn |
| Dec 31, 2024 | 2.60 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 3.78 Mn |
| Mar 31, 2024 | 3.61 Mn |
| Dec 31, 2023 | 2.63 Mn |
| Sep 30, 2023 | 2.79 Mn |
| Jun 30, 2023 | 3.47 Mn |
| Mar 31, 2023 | 4.61 Mn |
| Dec 31, 2022 | 4.90 Mn |
| Sep 30, 2022 | 6.80 Mn |
| Jun 30, 2022 | 7.67 Mn |
| Mar 31, 2022 | 8.57 Mn |
| Dec 31, 2021 | 5.92 Mn |
| Sep 30, 2021 | 6.54 Mn |